OSE Immunotherapeutics targets mid-2027 validation for subcutaneous lusvertikimab in inflammatory bowel disease

• OSE Immunotherapeutics reported enrollment in its Phase 3 ARTEMIA trial of Tedopi in second-line NSCLC remains on track for completion by end-December 2026.
• The trial’s interim futility readout was pushed to early 2027, reflecting slower-than-expected event accumulation that could delay a key decision point.
• In ovarian cancer, positive Phase 2 TEDOVA topline results were already presented, supporting further development of Tedopi in combination therapy.
• A Phase 2 Combi-TED study in NSCLC will present topline results at ESMO on Oct. 25, 2026, offering a near-term catalyst.
• For lusvertikimab, a Phase I study of a subcutaneous formulation is slated for submission by end-2026, with results expected by mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSE Immunotherapeutics SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280130OMX_____CNEWS_EN_GNW1001274817_en) on September 28, 2026, and is solely responsible for the information contained therein.